Trade Name Review May Shift To Firms, But FDA Unclear Which Tests To Use
Executive Summary
FDA is asking firms to use computerized methods and algorithms that can detect product name similarities as part of a pilot designed to expedite name review. The program, under which companies would generate their own data and submit it to FDA for review, will be discussed at a June 5-6 public meeting
You may also be interested in...
FDA Dangles Trade Name Review Pilot, But Industry Still Looking For The Bait
The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them
FDA Dangles Trade Name Review Pilot, But Industry Still Looking For The Bait
The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them
Drug Name Battles May Be Waged More Publicly; FDA Petitioned On Zentase
FDA's efforts to pre-empt trade name conflicts by shifting decisions to earlier in the application process are still just getting off the ground. In one case, though, a company has taken matters into its own hands and is pressing the agency to make an early, public determination about whether a proposed brand name is acceptable